Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Clinical trial NCT07285239 · RECRUITING
Trial details
- NCT number
- NCT07285239
- Sponsor
- PrECOG, LLC.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-01
- Primary completion
- 2031-11-01
- Enrollment
- 500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.